Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

Abstract

Chemotherapy-induced nausea and vomiting (CINV) are distressing side effects of chemotherapy. Neurokinin-1 receptor antagonists (NK1-RAs) have been incorporated in the contemporary management of CINV. However, clinical studies on NK1-RAs have shown mixed results in reducing CINV risk. Most studies focused on the use of aprepitant (APR) and casopitant (CAS) in breast cancer patients receiving AC-type (doxorubicin and cyclophosphamide) chemotherapy. In this study, we compared the study design and clinical efficacies of these NK1-RAs in reducing CINV risk. Among the selected eight studies, 4 APR Randomized Controlled Trials (RCTs), 2 APR Observational Studies (OSs) and 2 CAS RCTs were identified. Patient-related characteristics such as the proportion of females (60.0% - 100.0%), age (46.5 - 59.5 years), histories of motion (5.6% - 47.0% in NK1-RA arms) and morning sicknesses (14.2% - 45.0% in NK1-RA arms) and types of antiemetic regimens; as well as chemotherapy-related characteristics such as the proportion of patients on AC chemotherapy (15.0% - 100.0%) varied greatly. In terms of efficacies, both APR and CAS improved overall CR and vomiting in majority of the studies. None of the studies, however, demonstrated that NK1-RA could provide adequate nausea control. To conclude, NK1-RAs are effective in improving vomiting and overall CR, but not useful in controlling nausea or attaining CC, the ideal CINV endpoint. A shift in paradigm is needed for future CINV research. As healthcare providers continue to strive for optimum CINV control in their patients, we hope this review can help them make better informed clinical decisions.

Share and Cite:

K. Yap, C. Leong and A. Chan, "Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?," Journal of Cancer Therapy, Vol. 3 No. 1, 2012, pp. 90-102. doi: 10.4236/jct.2012.31012.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] C. C. Sun, D. C. Bodurka, C. B. Weaver, et al., “Rankings and Symptom Assessments of Side Effects from Chemotherapy: Insights from Experienced Patients with Ovarian Cancer,” Supportive Care in Cancer, Vol. 13, No. 4, 2005, pp. 219-227. doi:10.1007/s00520-004-0710-6
[2] A. Fabi, M. Barduagni, S. Lauro, et al., “Is Delayed Chemotherapy-Induced Emesis Well Managed in Oncological clinical Practice? An Observational Study,” Supportive Care in Cancer, Vol. 11, No. 3, 2003, pp. 156-161. doi:10.1007/s00520-002-0427-3
[3] S. Grunberg, R. Deuson, P. Mavros, et al., “Incidence of Chemotherapy-Induced Nausea and Emesis after Modern Antiemetics: Perception versus Reality,” Cancer, Vol. 100, No. 10, 2004, pp. 2261-2268. doi:10.1002/cncr.20230
[4] K. G. Reddy, R. J. Gralla and P. J. Hesketh, “Novel Neurokinin-1 Antagonists as Antiemetics for the Treatment of Chemotherapy-Induced Emesis,” Supportive Cancer Therapy, Vol. 3, No. 3, 2006, pp. 140-142. doi:10.3816/SCT.2006.n.011
[5] M. Kris, P. Hesketh, M. Somerfield, et al., “American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,” Journal of Clinical Oncology, Vol. 24, No. 18, 2006, pp. 2932-2947. doi:10.1200/JCO.2006.06.9591
[6] National Comprehensive Cancer Network, “NCCN Clinical Practice Guidelines in Oncology—Antiemesis (Version I.2012),” 2011. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
[7] R. J. Gralla, F. Roila, M. Tonato and J. Herrstedt, “MASCC/ ESMO Antiemetic Guideline 2011,” 2011. http://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2011.pdf
[8] R. Twycross and A. Wilcock, “Nausea and Vomiting,” Symptom Management in Advanced Cancer, Radcliffe Medical Press, Oxford, 2002, pp. 104-110.
[9] S.-C. J. Yeung, C. P. Escalante and R. F. Gagel, “Medical Care of Cancer Patients,” People’s Medical Publishing House, USA, 2009.
[10] M. P. Curran and D. M. Robinson, “Aprepitant: A Review of Its Use in the Prevention of Nausea and Vomiting,” Drugs, Vol. 69, No. 13, 2009, pp. 1853-1878. doi:10.2165/11203680-000000000-00000
[11] J. Herrstedt, W. Arpornwirat, A. Shaharyar, et al., “Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy,” Journal of Clinical Oncology, Vol. 27, No. 32, 2009, pp. 5363-5369. doi:10.1200/JCO.2009.21.8511
[12] B. L. Rapoport, K. Jordan, J. A. Boice, et al., “Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with a Broad Range of Moderately Emetogenic Chemotherapies and Tumor Types: A Randomized, Double-Blind Study,” Supportive Care in Cancer, Vol. 18, No. 4, 2010, pp. 423-431. doi:10.1007/s00520-009-0680-9
[13] Health Promotion Board National Registry of Diseases Office, “Singapore Cancer Registry Interim Report: Trends in Cancer Incidence in Singapore 2004-2008,” 2010. http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/Cancer_Trends_Report0408_web_v2.pdf
[14] B. Fisher, S. Anderson, D. L. Wickerham, et al., “Increased Intensification and Total Dose of Cyclophosphamide in a Doxorubicin-Cyclophosphamide Regimen for the Treatment of Primary Breast Cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22,” Journal of Clinical Oncology, Vol. 15, No. 5, 1997, pp. 1858-1869.
[15] B. Fisher, A. M. Brown, N. V. Dimitrov, et al., “Two Months of Doxorubicin-Cyclophosphamide with and without Interval Reinduction Therapy Compared with 6 Months of Cyclophosphamide, Methotrexate and Fluorouracil in Positive-Node Breast Cancer Patients with Tamoxifen-Nonresponsive Tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15,” Journal of Clinical Oncology, Vol. 8, No. 9, 1990, pp. 1483-1496.
[16] J. M. Nabholtz, C. Falkson, D. Campos, et al., “Docetaxel and Doxorubicin Compared with Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic breast Cancer: Results of a Randomized, Multicenter, Phase III Trial,” Journal of Clinical Oncology, Vol. 21, No. 6, 2003, pp. 968-975. doi:10.1200/JCO.2003.04.040
[17] T. Grote, J. Hajdenberg, A. Cartmell, et al., “Combination Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Palonosetron, Dexamethasone and Aprepitant,” Journal of Supportive Oncology, Vol. 4, No. 8, 2006, pp. 403-408.
[18] W. Arpornwirat, I. Albert, V. L. Hansen, et al., “Phase 2 Trial Results with the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy,” Cancer, Vol. 115, No. 24, 2009, pp. 5807-5816. doi:10.1002/cncr.24630
[19] J. Herrstedt, H. B. Muss, D. G. Warr, et al., “Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Emesis over Multiple Cycles of Moderately Emetogenic Chemotherapy,” Cancer, Vol. 104, No. 7, 2005, pp. 1548-1555. doi:10.1002/cncr.21343
[20] P. J. Hesketh, J. Younger, P. Sanz-Altamira, et al., “Aprepitant as Salvage Antiemetic Therapy in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide,” Supportive Care in Cancer, Vol. 17, No. 8, 2009, pp. 1065-1070. doi:10.1007/s00520-008-0545-7
[21] D. G. Warr, P. J. Hesketh, R. J. Gralla, et al., “Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer after Moderately Emetogenic Chemotherapy,” Journal of Clinical Oncology, Vol. 23, No. 12, 2005, pp. 2822-2830. doi:10.1200/JCO.2005.09.050
[22] W. Yeo, F. K. F. Mo, J. J. S. Suen, et al., “A randomized study of Aprepitant, Ondansetron and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients Receving Moderately Emetogenic Chemotherapy,” Breast Cancer Research and Treatment, Vol. 113, No. 3, 2009, pp. 529-535. doi:10.1007/s10549-008-9957-9
[23] M. S. Aapro and C. M. Walko, “Aprepitant: Drug-Drug Interactions in Perspective,” Annals of Oncology, Vol. 21, No. 12, 2010, pp. 2316-2323. doi:10.1093/annonc/mdq149
[24] National Cancer Institute, “Common Terminology Criteria for Adverse Events v3.0 (CTCAE),” 2006. http://www.eortc.be/services/doc/ctc/ctcaev3.pdf
[25] R. Gralla, M. Lichinitser, S. Van der Vegt, et al., “Palonosetron Improved Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron with Ondansetron,” Annals of Oncology, Vol. 14, No. 10, 2003, pp. 1570-1577. doi:10.1093/annonc/mdg417
[26] P. J. Hesketh, M. Aapro, J. C. Street and A. D. Carides, “Evaluation of Risk Factors Predictive of Nausea and Vomiting with Current Standard-of-Care Antiemetic Treatment: Analysis of Two Phase III Trials of Aprepitant in Patients Receiving Cisplatin-Based Chemotherapy,” Supportive Care in Cancer, Vol. 18, No. 9, 2010, pp. 1171-1177. doi:10.1007/s00520-009-0737-9
[27] D. G. Warr, J. C. Street and A. D. Carides, “Evaluation of Risk Factors Predictive of Nausea and Vomiting with Current Standard-of-Care Antiemetic Treatment: Analysis of Phase 3 Trial of Aprepitant in Patients Receiving Adriamycin-Cyclophosphamide-Based Chemotherapy,” Supportive Care in Cancer, Vol. 19, No. 6, 2011, pp. 807-813. doi:10.1007/s00520-010-0899-5
[28] V. Shih, S. W. Hee and A. Chan, “Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide,” Annals of Pharmacotherapy, Vol. 43, No. 3, 2009, pp. 444-452. doi:10.1345/aph.1L437
[29] J. K. Lamba, Y. S. Lin, E. G. Schuetz and K. E. Thummel, “Genetic Contribution to Variable Human CYP3A-Mediated Metabolism,” Advanced Drug Delivery Reviews, Vol. 54, No. 10, 2002, pp. 1271-1294. doi:10.1016/S0169-409X(02)00066-2
[30] R. I. Sanchez, R. W. Wang, D. J. Newton, et al., “Cytochrome P450 3A4 Is the Major Enzyme Involved in the Metabolism of the Substance P Receptor Antagonist Aprepitant,” Drug Metabolism and Disposition, Vol. 32, No. 11, 2004, pp. 1287-1292. doi:10.1124/dmd.104.000216
[31] J. F. Solus, B. J. Arietta, J. R. Harris, et al., “Genetic Variation in Eleven Phase I Drug Metabolism Genes in an Ethnically Diverse Population,” Pharmacogenomics, Vol. 5, No. 7, 2004, pp. 895-931. doi:10.1517/14622416.5.7.895
[32] GlaxoSmithKline, “Withdrawal of Marketing Authorisation Application for Zunrisa (as Casopitant Mesilate), 50 mg and 150 mg film coated tablets—EMEA/H/C/1040,” 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500060224.pdf
[33] P. J. Hesketh and P. Sanz-Altamira, “Aprepitant, Dexamethasone, and Palonosetron in the Prevention of Doxorubicin/Cyclophosphamide-Induced Nausea and Vomiting,” Supportive Care in Cancer, epub ahead of print, 2011. doi:10.1007/s00520-011-1312-8
[34] E. Basch, A. A. Prestrud, P. J. Hesketh, et al., “Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,” Journal of Clinical Oncology, Vol. 29, No. 31, 2011, pp. 4189-4198. doi:10.1200/JCO.2010.34.4614
[35] M. Majem, M. E. Moreno, N. Calvo, et al., “Perception of Healthcare Providers versus Patient Reported Incidence of Chemotherapy-Induced Nausea and Vomiting after the Addition of NK-1 Receptor Antagonists,” Supportive Care in Cancer, Vol. 19, No. 12, 2011, pp. 1983-1990. doi:10.1007/s00520-010-1042-3
[36] S. M. Grunberg, D. Warr, R. J. Gralla, et al., “Evaluation of New Antiemetic Agents and Definition of Antineoplastic Agent Emetogenicity—State of the Art,” Supportive Care in Cancer, Vol. 19 No. Supplement 1, 2011, pp. S43-S47. doi:10.1007/s00520-010-1003-x
[37] R. M. Navari, S. E. Gray and A. C. Kerr, “Olanzapine versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial,” Journal of Supportive Oncology, Vol. 9, No. 5, 2011, pp. 188-195. doi:10.1016/j.suponc.2011.05.002
[38] D. A. Perwitasari, H. Gelderblom, J. Atthobari, et al., “Anti-emetic Drugs in Oncology: Pharmacology and Individualization by Pharmacogenetics,” International Journal of Clinical Pharmacy, Vol. 33, No. 1, 2011, pp. 33-43. doi:10.1007/s11096-010-9454-1
[39] T. Takahashi, Y. Nakamura, A. Tsuya, et al., “Pharmacokinetics of Aprepitant and Dexamethasone after Administration of Chemotherapeutic Agents and Effects of Plasma Substance P Concentration on Chemotherapy-Induced Nausea and Vomiting in Japanese Cancer Patients,” Cancer Chemotherapy and Pharmacology, Vol. 68, No. 3, 2011, pp. 653-659. doi:10.1007/s00280-010-1519-2
[40] T. J. Gan, J. Gu, N. Singla, et al., “Rolapitant for the Prevention of Postoperative Nausea and Vomiting: A Prospective, Double-Blinded, Placebo-Controlled Randomized trial,” Anesthesia and Analgesia, Vol. 112, No. 4, 2011, pp. 804-812. doi:10.1213/ANE.0b013e31820886c3
[41] K. Dhanachandra Singh, M. Karthikeyan, P. Kirubakaran and S. Nagamani, “Pharmacophore Filtering and 3D-QSAR in the Discovery of New JAK2 Inhibitors,” Journal of Molecular Graphics and Modelling, Vol. 30, 2011, pp. 186-197. doi:10.1016/j.jmgm.2011.07.004
[42] A. Weaver, A. M. Young, J. Rowntree, et al., “Application of Mobile Phone Technology for Managing Chemo- therapy-Associated Side-Effects,” Annals of Oncology, Vol. 18, No. 11, 2007, pp. 1887-1892. doi:10.1093/annonc/mdm354
[43] K. Y.-L. Yap, X. R. Yak, V. Shih, W. K. Chui and A. Chan, “Application of Unsupervised Learning in Clinical Oncology Practice—Exploring Anxiety Characteristics in Chemotherapy-Induced Nausea and Vomiting through Principal Variables,” Journal of Computing, Vol. 2, No. 7, 2010, pp. 163-171.

Journals Menu
Follow SCIRP
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.